Hexarelin research: what the studies have looked at

This page summarises the published research on hexarelin, for reference. It states what each study investigated and in whom, not an effect to expect, and it is not medical advice. Hexarelin reached human trials but is not an approved medicine; what we supply is a research chemical for laboratory use only.

What hexarelin is

Hexarelin is a synthetic six-amino-acid growth-hormone secretagogue related to GHRP-6, acting on the ghrelin receptor (GHS-R1a) to release growth hormone. It reached human clinical studies but has not been approved as a medicine.

What the studies investigated

Ghigo et al. (1994), Journal of Clinical Endocrinology and Metabolism 78(3):693-698. Human. Investigated the growth-hormone response across different routes of administration Source.

Imbimbo et al. (1994), European Journal of Clinical Pharmacology 46(5):421-425. Human, rising dose. Investigated the dose-dependent growth-hormone response Source.

Tivesten et al. (2000), Endocrinology 141(1):60-66. Rat, after myocardial infarction. Investigated haemodynamic effects, where a cardiac mechanism was not established Source.

Mechanism, as described in the literature

The literature describes hexarelin as a ghrelin-receptor (GHS-R1a) agonist that releases growth hormone, studied in humans across routes and doses and in animals for possible effects on the heart. The human work is mechanistic and dose-finding; the cardiac findings in animals are exploratory and a mechanism was not established.

The material we supply

We supply hexarelin as a research chemical, released against a written specification with a batch certificate of analysis. It is not an approved medicine and is not for human or animal use. For the vial sizes, the price per mg and how to order, see the hexarelin compound page; the COA lookup pulls the certificate for any batch. The references above link to each study’s record; this summary is for research and educational reference only.